Performance of stented biological valves for pulmonary valve replacement

Authors:
  • CBC. Buchholz
    C. Buchholz
  • AKA.M. Koch
    A.M. Koch
  • APA. Purbojo
    A. Purbojo
  • OTO. Toka
    O. Toka
  • SDS. Dittrich
    S. Dittrich
  • ARA. Rüffer
    A. Rüffer

Abstract
Objective: Our experience with isolated stented biological valves (SBV) in pulmonary position without conduit was retrospectively assessed. Methods: Thirty-nine stented biological valves (17 Edwards SAV; 12 Edwards CEP; 4 Sorin Mitroflow; 4 Sorin SOPRANO; 4 Sorin MORE) were implanted between 2000 and 2010. Median valve size was 23 mm (range, 19-27); median patients age and weight were 20.1 years (range, 5-72) and 60 kg (range, 14-110), respectively. Thirty-five patients (90%) had previous cardiac surgery. Main diagnoses were tetralogy of Fallot (54%) and pulmonary atresia (18%). Results: There was no early mortality. Follow-up was complete with a mean duration of 8.9 ± 3.8 years. Two patients died late after 5.8 and 6.1 years, respectively, both not SBV related. In 12 patients (31%) SBV has been replaced by surgery (n = 9) or intervention (n = 3). Reason for SBV failure were valve stenosis (n = 9) or stenosis and insufficiency (n = 3). Additionally, 2 RVOT-aneurysms and 1 endocarditis were diagnosed. Freedom from SBV-replacement by surgery or intervention was 95%, 84% and 77% after 3, 5 and 10 years, respectively. Risk factors for SBV-replacement by univariate analysis were valve size ≤21 mm (p = 0.050), lower age (p < 0.01) and pulmonary atresia (p = 0.006). The only independent risk factor by cox-regression analysis was lower age (hazard ratio: 0.87, confidence interval: 0.76-0.99; p = 0.036). Conclusion: SBV in pulmonary position revealed encouraging long-term results. Younger patient age and pulmonary atresia seem to be associated with higher risk of SBV failure.